Bégin, 938 patient convalescent plasma late treatment RCT: 13% higher mortality [p=0.33] and 16% higher combined mortality/intubation [p=0.18] https://c19p.org/begin
copied to clipboard
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
et al., Nature Medicine, doi:10.1038/s41591-021-01488-2
RCT 940 hospitalized patients, 614 assigned to convalescent plasma, showing no significant differences. NCT04348656.
|
risk of death, 13.0% higher, RR 1.13, p = 0.33, treatment 156 of 625 (25.0%), control 69 of 313 (22.0%), day 90.
|
|
risk of death, 12.0% higher, RR 1.12, p = 0.40, treatment 141 of 614 (23.0%), control 63 of 307 (20.5%), day 30.
|
|
risk of death/intubation, 16.0% higher, RR 1.16, p = 0.18, treatment 199 of 614 (32.4%), control 86 of 307 (28.0%), primary outcome.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Bégin et al., 9/9/2021, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 32 authors, average treatment delay 8.0 days, trial NCT04348656.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.